Histone deacetylase inhibitors: Keeping momentum for neuromuscular and cardiovascular diseases treatment

被引：39

作者：

Colussi, Claudia ^{[2
]}

Illi, Barbara ^{[2
]}

Rosati, Jessica ^{[1
]}

Spallotta, Francesco ^{[1
]}

Farsetti, Antonella ^{[3
]}

Grasselli, Annalisa ^{[3
,4
]}

Mai, Antonello ^{[5
]}

Capogrossi, Maurizio C. ^{[1
]}

Gaetano, Carlo ^{[1
]}

机构：

[1] Ist Dermopat Immacolata, Lab Patol Vasc, I-00167 Rome, Italy

[2] Ist Cardiol Monzino, Lab Biol Vasc & Med Rigenerat, Milan, Italy

[3] CNR, Ist Neurobiol & Med Mol, Rome, Italy

[4] Ist Nazl Ricovero & Cura Anziano, Ancona, Italy

[5] Univ Roma La Sapienza, Dipartimento Sci Chim, Rome, Italy

来源：

PHARMACOLOGICAL RESEARCH | 2010年 / 62卷 / 01期

关键词：

Neuromuscular disorders; HDAC; HDAC inhibitors; Cardiovascular diseases; CLASS-II; NITRIC-OXIDE; CARDIAC-HYPERTROPHY; MOUSE MODEL; SODIUM-BUTYRATE; HDAC INHIBITION; DYSTROPHY; EXPRESSION; MUSCLE; HEART;

D O I：

10.1016/j.phrs.2010.02.014

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Histone deacetylases (HDACs) are enzymes with a pleiotropic range of intracellular localizations and actions. They are principally involved in the withdrawal of acetyl-groups from a large number of nuclear and cytoplasmic proteins including nuclear core histones as well as cytoskeletal proteins and metabolically relevant enzymes. Initial findings indicated that HDAC inhibitors (DIs) could be successfully applied in a variety of cancer treatment protocols as a consequence of their anti-proliferative and pro-apoptotic properties. Recent observations, however, enlightened the important therapeutic effects of DIs in experimental animal models for arthritis, neurodegenerative and neuromuscular disorders, heart ischemia, cardiac hypertrophy, heart failure and arrhythmias. A small number of clinical trials are now open or planned for the near future to verify the therapeutic properties of DIs in non-cancer-related diseases. This review summarizes some of the most important observations and concepts aroused by the most recent experimental application of DIs to neuromuscular and cardiac diseases. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：3 / 10

页数：8

共 127 条

[1] Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders [J].

Abe, Ted ;

Zukin, R. Suzanne .

CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (01) :57-64

[2] Epigenetic regulation of airway inflammation [J].

Adcock, Ian M. ;

Tsaprouni, Loukia ;

Bhavsar, Pankaj ;

Ito, Kazuhiro .

CURRENT OPINION IN IMMUNOLOGY, 2007, 19 (06) :694-700

[3]

Adcock Ian M, 2005, COPD, V2, P445

[4] Histone Deacetylases 1 and 2 Form a Developmental Switch That Controls Excitatory Synapse Maturation and Function [J].

Akhtar, Mohd W. ;

Raingo, Jesica ;

Nelson, Erika D. ;

Montgomery, Rusty L. ;

Olson, Eric N. ;

Kavalali, Ege T. ;

Monteggia, Lisa M. .

JOURNAL OF NEUROSCIENCE, 2009, 29 (25) :8288-8297

[5] Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors [J].

Antos, CL ;

McKinsey, TA ;

Dreitz, M ;

Hollingsworth, LM ;

Zhang, CL ;

Schreiber, K ;

Rindt, H ;

Gorczynski, RJ ;

Olson, EN .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (31) :28930-28937

[6] Inclusion Body Myositis: A Degenerative Muscle Disease Associated with Intra-Muscle Fiber Multi-Protein Aggregates, Proteasome Inhibition, Endoplasmic Reticulum Stress and Decreased Lysosomal Degradation [J].

Askanas, Valerie ;

Engel, W. King ;

Nogalska, Anna .

BRAIN PATHOLOGY, 2009, 19 (03) :493-506

[7] Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy [J].

Avila, Amy M. ;

Burnett, Barrington G. ;

Taye, Addis A. ;

Gabanella, Francesca ;

Knight, Melanie A. ;

Hartenstein, Parvana ;

Cizman, Ziga ;

Di Prospero, Nicholas A. ;

Pellizzoni, Livio ;

Fischbeck, Kenneth H. ;

Sumner, Charlotte J. .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (03) :659-671

[8] A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas [J].

Balasubramanian, S. ;

Ramos, J. ;

Luo, W. ;

Sirisawad, M. ;

Verner, E. ;

Buggy, J. J. .

LEUKEMIA, 2008, 22 (05) :1026-1034

[9] Reduced histone deacetylase in COPD - Clinical implications [J].

Barnes, PJ .

CHEST, 2006, 129 (01) :151-155

[10] Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment [J].

Barnes, PJ .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (06) :1111-1121

← 1 2 3 4 5 6 7 8 9 10 →